Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
31 Mayo 2023 - 3:30PM
Business Wire
Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working
to turn cells into powerful therapeutics, today announced that
Michele Korfin, Chief Operating and Chief Commercial Officer, will
present corporate highlights at the upcoming Jefferies Healthcare
Conference on June 8, 2023 at 9:30 a.m. ET.
Ms. Korfin’s presentation will include an overview of the
company’s corporate strategy and commercial strategy for
Omisirge®.
The webcast will be available on the “Investors & Media”
section of Gamida Cell’s website at www.gamida-cell.com, and will
be available for at least 14 days following the event.
About Gamida Cell
Gamida Cell is a cell therapy pioneer working to turn cells into
powerful therapeutics. The company’s proprietary nicotinamide (NAM)
technology leverages the properties of NAM to enhance and expand
cells, creating allogeneic cell therapy products and candidates
that are potentially curative for patients with hematologic
malignancies. These include Omisirge®, an FDA-approved nicotinamide
modified allogeneic hematopoietic progenitor cell therapy, and
GDA-201, an intrinsic NK cell therapy candidate being investigated
for the treatment of hematologic malignancies. For additional
information, please visit www.gamida-cell.com or follow Gamida Cell
on LinkedIn, Facebook, Twitter and Instagram.
Omisirge® is a registered trademark of Gamida Cell Inc. © 2023
Gamida Cell Inc. All Rights Reserved.
Forward-Looking Statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to the potentially life-saving or
curative therapeutic and commercial potential of Omisirge®
(omidubicel-onlv), the company’s plans for commercial or strategic
partnerships to support the launch of Omisirge. Any statement
describing Gamida Cell’s goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are
subject to a number of risks, uncertainties and assumptions
including those related to clinical, scientific, regulatory and
technical developments and those inherent in the process of
developing and commercializing product candidates that are safe and
effective for use as human therapeutics. In light of these risks
and uncertainties, and other risks and uncertainties that are
described in the Risk Factors section and other sections of Gamida
Cell’s Quarterly Report on Form 10-Q, filed with the Securities and
Exchange Commission (SEC) on May 15, 2023, and other filings that
Gamida Cell makes with the SEC from time to time (which are
available at www.sec.gov), the events and circumstances discussed
in such forward-looking statements may not occur, and Gamida Cell’s
actual results could differ materially and adversely from those
anticipated or implied thereby. Although Gamida Cell’s
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by Gamida Cell. As a result, you are cautioned not
to rely on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230531005879/en/
Investor and Media Contact: Dan Boyle Orangefiery
media@orangefiery.com 1-818-209-1692
Gamida Cell (NASDAQ:GMDA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Gamida Cell (NASDAQ:GMDA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024